Ignite Creation Date:
2024-10-25 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06539195
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma TAI-SHAN9
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Open-label Multicenter Study to Evaluate the Efficacy Safety Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will treat patients with DLBCL whose disease comes back or is not responding to prior therapy This study will assess the anti-tumor activity of DZD8586 as monotherapy It will help to understand what type of side effects may occur with the drug treatment It will also measure the levels of drug in the body
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None